Form 4: CRISPR Therapeutics COO Julianne Bruno Reports Stock Transactions

Julianne Bruno, COO of CRISPR Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• On February 18, 2025, Julianne Bruno, the Chief Operating Officer of CRISPR Therapeutics, had 650 restricted stock units vest, which were then converted into common shares.
• Following the vesting, Ms. Bruno sold 333 common shares on February 19, 2025, at a price of $52.8 per share to cover tax withholding obligations.
• After these transactions, Ms. Bruno directly owns 7,062 common shares and indirectly owns 7,088 common shares through The Julianne Bruno 2022 GRAT.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, with no inherent positive or negative sentiment. It's a neutral disclosure of information.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.

Stakeholder Impact

• The sale of shares by a company executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale (tax obligations).

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Julianne Bruno, Stock Transaction, Form 4, Restricted Stock Units, Beneficial Ownership, COO